Sign in
CompletedNo phase

Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.

Key facts

Who runs it
Procare Health Iberia S.L.
Where
Spain19 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
164 people enrolled
Started
25 Sept 2019
Ended
30 Jun 2024
Type of study
Interventional, 4 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Papilocare vaginal gel
Record updated
2 September 2026

Who can take part

Age
30 years to 65 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Woman between the ages of 30 and 65 (both inclusive)
  • Able to read and understand the Patient Information Sheet and the Informed Consent form
  • Acceptance in the participation of the essay and signature of the Informed Consent form
  • ASC-US or LSIL or AG-US cytological result (maximum 3 months prior to inclusion) with concordant colposcopic image (performed at the screening visit)
  • High risk HPV positive by PCR performed at screening visit
  • Is able, at the discretion of the researcher, to comply with the requirements of the trial and without hindrance to follow the instructions and assessments throughout it

Who cannot take part

  • Clinically relevant immune system alterations, or any other autoimmune disease or in treatment with immunosuppressants
  • Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening visit)
  • Surgical cervical excision in the last year or total hysterectomy
  • Previous history of gynecological cancer
  • Participation in any other clinical trial at present or in the 4 weeks prior to the inclusion of the trial
  • Any planned surgery that prevents the correct compliance with the guidelines
  • Other symptomatic vulvovaginal infections
  • Contraindications for the use of Papilocare® gel or known allergies to any of its components
  • Women of childbearing age who do not use effective contraceptive methods, pregnant women, with suspicion of pregnancy or woman who are breastfeeding
  • To had been vaccinated against HPV
  • Use of vaginal contraceptives or other vaginal hormonal treatments

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR. All the patients included in the study will be randomized (1:1:1:1) in 4 arms.

The 4 groups in the trial

  • A - papilocare alternative days treatmentTreatment being tested

    Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)

    Treatment: Papilocare vaginal gel

  • B - papilocare semiintensive treatmentTreatment being tested

    Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)

    Treatment: Papilocare vaginal gel

  • C - papilocare intensive treatmentTreatment being tested

    Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months

    Treatment: Papilocare vaginal gel

  • D - standard of careNo study treatment, for comparison

    Arm D: usual clinical practice - no treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ensayo clínico Aleatorizado, Abierto, Paralelo, Controlado, multicéntrico, Para Explorar la Eficacia Del Gel Vaginal Papilocare® en la reparación de la Mucosa Cervical Con Lesiones Causadas Por Virus Papiloma Humano de Alto Riesgo
Record updated
2 September 2026